21 results about "Atrophic spinal cord" patented technology

The present disclosure provides herein, inter alia, methods of treating patients diagnosed with amyotrophic lateral sclerosis (ALS).

Compositions and methods of using same for treating Amyotrophic Lateral Sclerosis (ALS) are provided. Accordingly there is provided a method of treating ALS in a human subject in need thereof, the method comprising intravenously (IV) administering to the subject 2 - 5 mg / kg of a peptide comprising an amino acid sequence as set forth in SEQ ID NO: 1. Also provided are compositions and unit dosage forms comprising a peptide comprising an amino acid sequence as set forth in SEQ ID NO: 1. 20 25 20 10 60 14 F eb 2 02 5 3 9 A B S T R A C T 2 0 2 5 2 0 1 0 6 0 1 4 F e b 2 0 2 5

The present invention relates to the treatment of an ALS patient with oral trimetazidine. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using the revised ALS Functional Rating Scale.

Provided herein is an anti-CD2 antibody or antigen binding fragment thereof for treating and / or preventing ALS in a subject in need thereof.

Abstract Dosage regimens for SOD1-targeting antisense oligonucleotides, and salts thereof, are provided. These dosage regimens find use in the treatment of subjects having or at risk of developing amyotrophic lateral sclerosis. Abstract 20 26 20 53 14 06 J ul 2 02 6 A b s t r a c t 2 0 2 6 2 0 5 3 1 4 0 6 J u l 2 0 2 6

The subject matter described here relates to methods, compositions, and vectors for treating Amyotrophic Lateral Sclerosis (ALS) in a subject in need thereof. In certain aspects, the method comprises administering to the subject a composition comprising adeno-associated viruses (AAVs), wherein the AAVs comprise a nucleic acid sequence comprising an enhancer sequence and encoding one or more transcription factors that control gene expression in nascent motor neurons, wherein the enhancer is capable of driving a motor-neuron specific expression of the one or more transcription factors and wherein the one or more transcription factors are expressed in motor neurons of the subject.

Provided herein is an anti-CD2 antibody or antigen binding fragment thereof for treating and / or preventing ALS in a subject in need thereof.

The disclosure provides a method of predicting the onset of clinical manifestations of amyotrophic lateral sclerosis (ALS) in a human, the method comprising (a) measuring phosphorylated neurofilament heavy chain (pNfH) and / or neurofilament light chain (NfL) levels in a subject, and (b) predicting the onset of ALS, wherein increased levels of pNfH and / or NfL signal the onset of clinical manifestations of ALS.

The invention discloses a bicyclic compound and an application of the bicyclic compound in a medicine, and particularly relates to a novel bicyclic compound and a medicine composition containing the novel bicyclic compound. The invention also relates to a method for preparing the compound, and application of the compound or the pharmaceutical composition in preparation of drugs for treating RIPK1 inhibitor mediated diseases and / or symptoms. The invention relates to the field of medicines, in particular to the application in preparing medicines for treating idiopathic pulmonary fibrosis, graft versus host disease, ulcerative colitis, rheumatoid arthritis, multiple sclerosis, amyotrophic lateral sclerosis, systemic inflammatory response syndrome, lupus erythematosus, Alzheimer's disease, psoriasis, non-alcoholic steatohepatitis and osteoarthritis.

The present invention discloses a small nucleic acid targeting the PIKfyve gene, as well as its preparation method, pharmaceutical composition, and uses. The small nucleic acid targeting the PIKfyve gene disclosed herein significantly reduces PIKfyve mRNA expression levels at the cellular level and significantly increases axon length in neuronal cells. In vivo validation demonstrates significant improvements in the physical function and survival of mice with amyotrophic lateral sclerosis (ALS). The small nucleic acid targeting the PIKfyve gene disclosed herein provides a novel approach for treating neurodegenerative diseases such as ALS, Parkinson's disease, and Alzheimer's disease.

The present invention relates inter alia to methods for identifying a substance useful for the prevention or treatment of a disease, disorder, or condition associated with altered NLRX1 activity, and uses of said substances in the prevention or treatment of a disease, disorder, or condition associated with altered NLRX1 activity, for example in the prevention or treatment of Parkinson's disease or amyotrophic lateral sclerosis.

Described herein are neonatal cardiac mesenchymal progenitor cells, an nMPC secretome, or an nMPC exosome for treating Amyotrophic Lateral Sclerosis (ALS) in a subject. One or more doses of neonatal cardiac mesenchymal progenitor cells, an nMPC secretome, an nMPC exosome, an nMPC total secretome, or a combination thereof can be administered to the subject. Neonatal cardiac mesenchymal progenitor cells can be allogeneic. The subject may also be administered one or more combination therapies.

The present invention provides a formulation of metformin and glibenclamide for the prevention and / or treatment of neurodegenerative diseases, preferably chosen among Parkinson's disease, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal dementia, Lewy body dementia, Huntington's disease and Alzheimer's disease.

It relates to a method for the treatment of famyotrophic lateral sclerosis (ALS) by an oligonucleotide agent, comprising the step of administering the subject a treatment effective amount of the oligonucleotide agent, wherein the oligonucleotide agent comprises a double-stranded targeting oligonucleotide (siRNA) and a non-targeting single-stranded accessory oligonucleotide (ACO). The method can be used in the treatment of ALS with and without SOD1 mutation. It also provides a safety therapeutic window and an effective dosing regimen for the treatment of ALS using the oligonucleotide agent.

The present disclosure provides herein, inter alia, methods of treating patients diagnosed with amyotrophic lateral sclerosis (ALS).

The disclosure provides methods of treating neurodegenerative conditions, for example, amyotrophic lateral sclerosis, using a regimen of a chlorite salt, for example, sodium chlorite. The long-term survival of subjects receiving sodium chlorite and placebo are compared.

Compounds described herein may be used for the treatment of neurodegenerative diseases linked to protein misfolding, including prion diseases, Alzheimer's disease, Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), and also other neurodegenerative, degenerative, metabolic and ischemic conditions. Indeed, NAD metabolism impairment is also a critical feature in brain ischemia / reperfusion injury, Wallerian degeneration, kidney failure, multiple sclerosis, aging, and metabolic disorders such as diabetes mellitus. Therapies that elevate or stabilize NAD levels may thus have broad potential for treating many severely debilitating neurological and metabolic conditions. Evidence is provided herein with compounds from 8 lead series for NAD restoring properties and for therapeutic efficacy in cellular and / or animal models of prion disease, PD and ALS.

The invention discloses a small nucleic acid targeting a PIKfyve gene as well as a preparation method, a pharmaceutical composition and application of the small nucleic acid. According to the small nucleic acid targeting the PIKfyve gene disclosed by the invention, the expression level of PIKfyve mRNA (messenger Ribonucleic Acid) is obviously reduced at the cellular level, and the axon length of neuronal cells is obviously increased; in-vivo verification shows that the body function and the survival condition of mice with amyotrophic lateral sclerosis can be remarkably improved. The small nucleic acid targeting the PIKfyve gene disclosed by the invention provides a new thought for treating neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinson's disease and Alzheimer's disease.

An application method of brucine for treating amyotrophic lateral sclerosis (ALS) is provided, relating to the field of biomedicines. It can delay a time of onset of ALS, prolong survival time of ALS patients, delay a weakening of limb extension ability, and improve limb grip strength.

Disclosed in the present invention are a bicyclic compound and a use thereof in a drug. The present invention specifically relates to a novel bicyclic compound and a pharmaceutical composition containing the compound. The present invention further relates to a method for preparing the compound and a use of the compound or the pharmaceutical composition in the preparation of a drug for treating a disease and / or condition mediated by an RIPK1 inhibitor, particularly in the preparation of a drug for treating diseases such as idiopathic pulmonary fibrosis, graft-versus-host disease, ulcerative colitis, rheumatoid arthritis, multiple sclerosis, amyotrophic lateral sclerosis, systemic inflammatory response syndrome, lupus erythematosus, Alzheimer's disease, psoriasis, non-alcoholic steatohepatitis, and osteoarthritis.

The invention described herein provides eIF2B agonist (e.g., COMPOUND 1 ) and uses thereof for treatment of diseases, especially neurodegenerative diseases, including vanishing white matter (VWM), Huntington's disease (HD), Charcot Marie Tooth syndrome (CMT), and Amyotropic Lateral Sclerosis (ALS).